Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581312 | 0.90 | CXCR2 (0.50) | RAB9ANPC1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL3577178 | 0.90 | HTT (0.44) | RAB9ANPC1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL3584536 | 0.88 | MAPT (0.45) | RAB9ANPC1SMN1; SMN2KMT2AHTT | |
| SCHEMBL3584626 | 0.88 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2KMT2AHTT | |
| SCHEMBL3574323 | 0.87 | KIF11 (0.40) | RAB9ANPC1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL3578975 | 0.85 | ALDH1A1 (0.47) | RAB9ANPC1KMT2AHTTMEN1 | |
| SCHEMBL1463379 | 0.85 | CXCR1 (0.49) | RAB9ANPC1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL13404779 | 0.80 | MGLL (0.47) | RAB9ANPC1SMN1; SMN2CXCR2HTT | |
| SCHEMBL3583939 | 0.79 | KDM4E (0.49) | RAB9ANPC1SMN1; SMN2CXCR2KMT2A | |
| SCHEMBL3575264 | 0.79 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | claimed |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | NEUSEARCH A/S (DK) | 2006-08-10 | — | — | US | claimed |
| US-7691891-B2 | Diphenylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2010-04-06 | — | — | US | disclosed |
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | disclosed |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | NEUSEARCH A/S (DK) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | KCNJ2, KCNH2, KCNH3 | RAB9A 3911/4885NPC1 808/4885SMN1; SMN2 2422/4885 |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | CLIC1, CLIC4, CLCN2 | RAB9A 4081/4885NPC1 434/4885SMN1; SMN2 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.